Oak Associates Ltd. OH Sells 73,338 Shares of Pfizer Inc. (NYSE:PFE)

Oak Associates Ltd. OH lowered its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 15.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 400,700 shares of the biopharmaceutical company's stock after selling 73,338 shares during the quarter. Oak Associates Ltd. OH's holdings in Pfizer were worth $10,631,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer in the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter worth $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PFE shares. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. UBS Group dropped their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.07.

Pfizer Trading Up 0.9 %

Pfizer stock traded up $0.19 during trading hours on Monday, reaching $22.10. 61,845,565 shares of the company's stock traded hands, compared to its average volume of 40,318,640. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $125.34 billion, a price-to-earnings ratio of 15.67, a PEG ratio of 0.64 and a beta of 0.67. The firm's 50 day moving average is $25.25 and its 200-day moving average is $26.38.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.10 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.